Diabetic Retinopathy: Current Management and Experimental Therapeutic Targets

被引:43
作者
Ali, Tayyeba K. [1 ,4 ,5 ]
El-Remessy, Azza B. [1 ,2 ,3 ,4 ]
机构
[1] Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA USA
[2] Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
[3] Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA
[4] Vet Affairs Med Ctr, Augusta, GA USA
[5] Univ Arkansas Med Sci, Dept Med & Ophthalmol, Little Rock, AR 72205 USA
来源
PHARMACOTHERAPY | 2009年 / 29卷 / 02期
关键词
diabetic retinopathy; diabetes therapies; neuroprotection; peroxynitrite; oxidative stress; ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; GLYCATION END-PRODUCTS; L-ARGININE TRANSPORT; KINASE-C ACTIVATION; OXIDATIVE STRESS; NITRIC-OXIDE; VITAMIN-E; VASCULAR DYSFUNCTION; REDUCTASE INHIBITORS;
D O I
10.1592/phco.29.2.182
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic retinopathy, a devastating ocular complication of diabetes mellitus, is the leading cause of blindness among working-age adults in the United States and is a serious public health problem throughout the world. Standard treatment is retinal laser photocoagulation, which is an invasive procedure with considerable limitations and adverse effects. Understanding the biochemical changes and molecular events that occur with diabetes as well as with retinopathy could lead to new and effective treatments. Research indicates an association between oxidative stress and the development of complications from diabetes, including retinopathy. Thus, many sites and sources of oxidative stress that may be involved in the development of diabetic retinopathy have been studied. However, in clinical trials, classic antioxidants have not been beneficial for patients with diabetes. Additional studies are needed to identify treatments that selectively target oxidative stress-mediated protein modification and thus prevent or at least delay diabetic retinopathy.
引用
收藏
页码:182 / 192
页数:11
相关论文
共 140 条
[1]   Diabetic retinopathy [J].
Aiello, LP ;
Gardner, TW ;
King, GL ;
Blankenship, G ;
Cavallerano, JD ;
Ferris, FL ;
Klein, R .
DIABETES CARE, 1998, 21 (01) :143-156
[2]   The potential role of PKC β in diabetic retinopathy and macular edema [J].
Aiello, LP .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S263-S269
[3]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[4]  
Aiello LP, 2005, DIABETES, V54, P2188
[5]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[6]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[7]   Role of NADPH oxidase and stat3 in statin-mediated protection against diabetic retinopathy [J].
Al-Shabrawey, Mohamed ;
Bartoli, Manuela ;
El-Remessy, Azza B. ;
Ma, Guochuan ;
Matragoon, Suraporn ;
Lemtalsi, Tahira ;
Caldwell, R. William ;
Caldwell, Ruth B. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (07) :3231-3238
[8]  
ALI TK, 2008, J DIABETES, V57, P889
[9]  
AMER DIABET ASSOC, 1993, DIABETES, V42, P1555
[10]  
[Anonymous], 1991, Ophthalmology, V98, P757